CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0323 (clinicaltrials.gov NCT No: NCT01083602)
Title:A phase II, multi-center, single arm, open label study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
Principal Investigator:Donna M. Weber
Treatment Agent:Bortezomib; Dexamethasone; LBH589
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
panobinostat, bortezomib, and dexamethasone can help to control MM. The safety
of these drugs will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase II
Treatment Agents:Bortezomib
Dexamethasone
LBH589
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Donna M. Weber
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults